Sold as Zeposia. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Ozanimod Hydrochloride (sold as Zeposia), first approved Mar 25, 2020, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Zeposia | Part D | $119M | +31% | 1,475 |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting · Bristol-Myers Squibb | Phase 3 | Recruiting | May 10, 2024 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesMultiple Sclerosis · Biogen | — | Active, not recruiting | Jan 18, 2023 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSMultiple Sclerosis, Relapsing-Remitting · The Cleveland Clinic | Phase 4 | Active, not recruiting | May 24, 2018 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA